<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343264</url>
  </required_header>
  <id_info>
    <org_study_id>RP2002-01</org_study_id>
    <nct_id>NCT01343264</nct_id>
  </id_info>
  <brief_title>Trimodality Therapy for Malignant Pleural Mesothelioma</brief_title>
  <official_title>Trimodality Therapy for Malignant Pleural Mesothelioma: Radical Pleurectomy, Followed by Adjuvant Chemotherapy With Cisplatin/Pemetrexed and Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HSK Wiesbaden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HSK Wiesbaden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of surgical resection in the management of Malignant Pleural Mesothelioma (MPM) is&#xD;
      still controversial. The selection criterion to perform either Extrapleural Pneumonectomy&#xD;
      (EPP) or Pleurectomy/Decortication (P/D) is dependent not only on the cardio-pulmonary status&#xD;
      of the patient, tumor stage and intraoperative findings but also on surgeons' decision and&#xD;
      philosophy. There are no established guidelines. Radical Pleurectomy (RP) competes against&#xD;
      EPP as surgical therapy modality. Both surgical approaches are cytoreductive treatment&#xD;
      options. The aim is to remove all gross disease and to achieve macroscopic complete&#xD;
      resection.&#xD;
&#xD;
      Originally P/D was a palliative option for controlling pleural effusion. But lung-sparing&#xD;
      surgery for MPM seems to be an alternative to patients unsuitable or unwilling to undergo EPP&#xD;
      in a multimodality therapy concept. Most studies evaluating multimodality therapies for MPM&#xD;
      are based on retrospective analyses and their interpretation is difficult because of&#xD;
      inhomogeneous patient groups studied.&#xD;
&#xD;
      The aim of our study was to analyze the feasibility and results of RP as surgical therapy&#xD;
      modality in a standardized trimodality therapy concept.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2002</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the overall 5-year survival rate.</measure>
    <time_frame>5-years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>3 months</time_frame>
    <description>Morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with treatment related deaths as a Measure of Safety and Tolerability</measure>
    <time_frame>3 months</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Occurence of tumor recurrence</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with malignant pleural mesothelioma prsentint at the Deparment of Thoracic&#xD;
        Surgery, HSK Wiesbaden&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of MPM (all subtypes)&#xD;
&#xD;
          -  Clinical T1-3, N0-2, M0 disease.&#xD;
&#xD;
          -  No prior treatment for MPM.&#xD;
&#xD;
          -  Adequate renal and liver function&#xD;
&#xD;
          -  Adequate cardio-pulmonary reserves&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with unresectable disease&#xD;
&#xD;
          -  Patients with an active infection that require systemic treatments&#xD;
&#xD;
          -  Patients with a concurrent active malignancy.&#xD;
&#xD;
          -  Patients with serious medical illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Schirren, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HSK Wiesbaden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Horst Schmidt Klinik, Department of Thoracic Surgery</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Schirren, MD, PhD</last_name>
      <phone>+49 611 433132</phone>
      <email>joachim.schirren@hsk-wiesbaden.de</email>
    </contact>
    <investigator>
      <last_name>Joachim Schirren, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Servet Bölükbas, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>April 5, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>April 26, 2011</last_update_submitted>
  <last_update_submitted_qc>April 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Joachim Schirren</name_title>
    <organization>HSK Wiesbaden</organization>
  </responsible_party>
  <keyword>Radical Pleurectomy</keyword>
  <keyword>Pleurectomy/decortication</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

